Company profile
NovoCure Ltd
NASDAQ:NVCRMedical/Dental Instruments
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| PEMBROLIZUMAB | phase3 | — | 263 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (15)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04892472 | phase2 | terminated | 2021-07-12 | 2025-01-10 | NovoCure GmbH | EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer |
| NCT06390059 | phase2 | completed | 2023-08-21 | 2025-11-18 | NovoCure Ltd. | EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma |
| NCT06556563 | phase3 | recruiting | 2025-02-03 | 2029-04-01 | NovoCure GmbH | EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma |
| NCT00916409 | phase3 | completed | 2009-06-01 | 2016-12-01 | NovoCure Ltd. | Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM) |
| NCT02973789 | phase3 | completed | 2016-12-01 | 2024-09-24 | NovoCure GmbH | Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR) |
FDA applications (0)
No records yet.